Optimize drug therapy and monitor patient adherence.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Mon, Wed, Sat
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transport 2 mL serum or plasma. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 2 weeks
Effective November 18, 2013
|Therapeutic Range:||20-80 ng/mL|
|Toxic:||Not well established|
Adverse effects may include dizziness, fatigue, somnolence and muscle weakness.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
80342 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
- zyprexa blood level
- zyprexa zydis